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Vulvovaginal candidiasis affects women of reproductive age, which represents approxi-
mately 15–25% of vaginitis cases. The present study aimed to isolate and characterize yeast
from the patients irrespective of the presentation of clinical symptoms. The isolates were
subjected to in vitro susceptibility proﬁle and characterization by molecular markers, which
intended to assess the distribution of species. A total of 40 isolates were obtained and iden-
tiﬁed through the CHROMagar, API20aux and by ITS and D1/D2 regions sequencing of DNAr
gene.  Candida albicans strains were genotyped by the ABC system and the isolates were
divided into two genotypic groups. The identity of the C. albicans, C. glabrata, C. guilliermondii,
C.  kefyr and Saccharomyces cerevisiae isolates was conﬁrmed by the multilocus analysis. The
strains of Candida, isolated from patients with complications, were found to be resistant
to nystatin but sensitive to ﬂuconazole, amphotericin B and ketoconazole, as observed by
in  vitro sensitivity proﬁle. The isolates from asymptomatic patients, i.e.,  the colonized group,
showed a dose-dependent sensitivity to the anti-fungal agents, ﬂuconazole and ampho-
tericin B. However, the isolates of C. albicans that belong to distinct genotypic groups showed
the  same in vitro susceptibility proﬁle.© 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
Microbiologia. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail: Queiroz.telles@uol.com.br (F. Queiroz-Telles).
ttp://dx.doi.org/10.1016/j.bjm.2016.01.005
517-8382/© 2016 Published by Elsevier Editora Ltda. on behalf of Soci
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/edade Brasileira de Microbiologia. This is an open access article
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Introduction
Vulvovaginal candidiasis (VVC) is a primary opportunistic
mycosis or secondary with endogenous or exogenous charac-
teristics. It is also classiﬁed as a sexually transmitted disease
(STD) and is caused by different species of Candida.1,2 The dis-
ease is characterized by inﬂammation of the genital mucosa
as a response to the yeast proliferation.3
The genus Candida includes approximately 300 heteroge-
neous species with different morphological and functional
features, and is currently found as a part of the normal ﬂora
in skin, digestive tract and mucous membrane, including the
human genito-urinary tract.4 Predominantly, VVC is caused
by C. albicans and its prevalence can reach 85–95%.1 How-
ever, infections caused by other species such as C. tropicalis,
C. glabrata, C. krusei,  C. parapsilosis, C. kefyr and C. lusitaniae
have been reported as well.1,4,5 According to literature these
species are part of the vaginal mucous microbiota and they
are present in 20–80% of healthy adult population, with clini-
cal manifestations in 10% of pre-menopausal patients, 5–10%
in menopausal and 30% of pregnant women.6,7
Vulvovaginal infection, caused by Candida spp., affects
women of reproductive age representing approximately
15–25% of the vaginitis cases.8 These microorganisms usually
remain hosted in the vaginal mucous only as colonizers; how-
ever, under inappropriate conditions the yeast reproduction
increases inducing expression of virulence factors, which sub-
sequently affects the mucous membrane, characteristic of the
symptomatic VVC.9
Identiﬁcation of strains that are isolated from VVC is cru-
cial to clarify the distribution of C. albicans in relation to
other species of Candida genus in different populations with
manifestations of the infection. In clinical practice, the yeast
identiﬁcation is based on morphological and biochemical
markers, including the automated methods.10,11 However, not
all the species are precisely identiﬁed by such procedures.
Therefore, molecular markers based on the sequencing of
variable domain (D1/D2) from the 26S region and internal tran-
scribed spacers (ITS) of the RNA gene were utilized in the
present study to enable identiﬁcation and detection of various
strains.12
VVC is not a notiﬁed disease and generally the drug
treatment is recommended based on the clinical diagnosis.
Epidemiological molecular studies are relevant in context of
establishment of species prevalence, elucidation of virulence
factors and mechanisms of drug resistance so as to support
the treatment protocols.13
A few studies have focused on the correlation of antifungal
susceptibility with clinical results in VVC.14 In spite of a con-
siderable enhancement in the resistance proﬁle among the
various Candida species, ﬂuconazole is still widely used for
treatment of VVC.1 Since it has been noticed that C. albicans
displays a variable sensitivity to azoles derivatives, it seems
crucial to identify its sensitivity proﬁle against various drugs
for a better therapeutic conduct.15In view of such grounds, the current work aimed to eval-
uate in vitro susceptibility and molecular characterization of
yeast from genus Candida that were isolated from the patients
with infection and the patients with no clinical symptoms, b i o l o g y 4 7 (2 0 1 6) 373–380
for elucidation of epidemiological aspects of vulvovaginal can-
didiasis.
Materials  and  methods
Test  organism
The present study analyzed vaginal material isolates from the
patients assisted by an outpatient clinic of Toco-gynecology
at the Clinical Hospital/UFPR, Paraná (Table 1). The study was
conducted from November 2011 to October 2012. The research
work was approved by the Ethical Committee of Federal Uni-
versity of Paraná Clinical. Samples from 133 women were
collected with their consent.
Casuistry
The study enrolled women, who were aged between 18 and
56 years, with or without VVC clinical symptoms, and who
had not been administered any drug treatment in the last six
months before collection of the samples. The patients were
divided into two groups: colonized patients (without clini-
cal symptoms) and infected patients.1 The infected patients
presented three or more  of the following clinical symp-
toms: typical discharge, vaginal itching, vulvovaginal burning,
dysuria and dyspareunia. Infected patient group was sub-
divided into two sub-groups: (i) complicated – which included
women with a history of recurrence infection; and (ii) uncom-
plicated – patients with sporadic episodes of the infection. The
exclusion criteria were age (under 18 and over 56), pregnancy
and women with immunosuppressive diseases and under
treatment.
Collection,  isolation  and  phenotypic  identiﬁcation
The samples were collected by swabs, and each sample was
sowed on Sabouraud Dextrose Agar medium followed by incu-
bation at ±30 ◦C for a period of 48–120 h as per the growth
parameters of each isolate. A presumptive identiﬁcation of iso-
lates was done by CHROMagar at 37 ◦C for 48 h.16 Some of the
isolates were identiﬁed by the API 20 AUX system (BioMérieux,
France).
Molecular  characterization  of  Candida  isolates
DNA from the isolates was extracted by physical mac-
eration of the samples in a mixture of silica/celite (2:1)
in CTAB (cetyltrimethylammonium bromide). The iso-
lated DNA was precipitated by CIA (acidic solution of
chloroform-isoamyl alcohol) followed by sequencing on
ABI3500 sequencer.17 For ITS sequencing, the following
primers were used: ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′)
and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) and the reaction
conditions of sequencing were as follows18: one cycle at
◦ ◦ ◦94 C for 2 min, followed by 30 cycles at (94 C for 30 s, 56 C
for 1 min, 72 ◦C for 1 min) and a ﬁnal extension at 72 ◦C
for 3 min.17 For ampliﬁcation of D1/D2 region, the primers
NL-1 (5′-GCATATCAATAAGCGGAGGAAAAG-3′) and NL-4
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Table 1 – List of reference strains and the clinical isolates.
Name Number of
reference
Substrate Geographical
indication
GenBank access
ITS D1/D1
Candida albicans CBS 562 Clinical isolate Australia EF567995 U45776
Candida dubliniensis CBS 7987 Clinical isolate Japan AB035589 U57685
Candida inconspícua CBS 180 Clinical isolate Australia AJ853766 U71062
Candida intermedia CBS 572 Clinical isolate Australia EF568011 U44809
Candida glabrata CBS 138 – Ireland AY198398 U44808
Candida haemulonii CBS 5149 – Spain JX459660 U44812
Candida tropicalis CBS 94 Clinical isolate Japan AB437068 U45749
Clavispora lusitaniae CBS 6986 Urine Bulgaria EF568049 U44817
Debaryomyces carsonii CBS 2285 Clinical isolate USA AJ853767 U45743
Kluyveromyces marxianus CBS 712 Clinical isolate Australia EF568057 U94924
Kluyveromyces lactis CECT1961 Environmental USA AJ401704 U94922
Meyerozyma guilliermondii CBS 2030 Clinical isolate Australia EF568003 U45709
Pichia fermentans L1B Environmental isolates UK FJ713081 U75726
Pichia membranifaciens 23 – Spain JQ410476 AJ508586
Pichia segobiensis CECT 10-210 – Spain DQ409166 U45742
Torulaspora delbrueckii CBS 1146 Clinical isolate Australia EF568083 AJ508558
Saccharomyces cerevisiae NRRL Y-12632 – USA AM900404 AY048154
Schizosaccharomyces pombe NRRL Y-12796 – USA AY251633 U40085
Candida glabrata HC01 Cervicovaginal contents Brazil KJ651873 KJ624025
Saccharomyces cerevisiae HC02 Cervicovaginal contents Brazil – KJ624026
Candida albicans HC03 Cervicovaginal contents Brazil KJ651903 KJ624027
Candida albicans HC04 Cervicovaginal contents Brazil KJ651904 KJ624028
Candida albicans HC05 Cervicovaginal contents Brazil KJ651905 KJ624029
Candida albicans HC06 Cervicovaginal contents Brazil KJ651906 KJ624030
Candida glabrata HC07 Cervicovaginal contents Brazil KJ651907 KJ624031
Candida guilliermondii HC08 Cervicovaginal contents Brazil KJ651908 KJ624032
Candida kefyr HC09 Cervicovaginal contents Brazil KJ651909 KJ624033
Candida glabrata HC10 Cervicovaginal contents Brazil KJ651910 KJ624034
Candida albicans HC11 Cervicovaginal contents Brazil KJ651874 KJ624035
Candida albicans HC12 Cervicovaginal contents Brazil KJ651875 KJ624036
Candida albicans HC13 Cervicovaginal contents Brazil – KJ624037
Candida albicans HC14 Cervicovaginal contents Brazil KJ651876 KJ624038
Candida albicans HC15 Cervicovaginal contents Brazil KJ651877 KJ624039
Candida albicans HC16 Cervicovaginal contents Brazil KJ651878 KJ624040
Candida albicans HC17 Cervicovaginal contents Brazil KJ651879 KJ624041
Candida albicans HC18 Cervicovaginal contents Brazil KJ651880 KJ624042
Candida albicans HC19 Cervicovaginal contents Brazil KJ651881 KJ624043
Candida albicans HC20 Cervicovaginal contents Brazil KJ651882 KJ624044
Candida albicans HC01IC Cervicovaginal contents Brazil KJ651883 KJ624045
Candida albicans HC02IC Cervicovaginal contents Brazil KJ651884 KJ624046
Candida dubliniensis HC03IC Cervicovaginal contents Brazil KJ651885 KJ624047
Candida albicans HC04IC Cervicovaginal contents Brazil KJ651886 KJ624048
Candida albicans HC05IC Cervicovaginal contents Brazil KJ651887 KJ624049
Candida albicans HC06IC Cervicovaginal contents Brazil KJ651888 KJ624050
Candida albicans HC07IC Cervicovaginal contents Brazil KJ651889 KJ624051
Candida albicans HC08IC Cervicovaginal contents Brazil KJ651890 KJ624052
Candida albicans HC09IC Cervicovaginal contents Brazil KJ651891 KJ624053
Candida albicans HC10IC Cervicovaginal contents Brazil KJ651892 KJ624054
Candida albicans HC11IC Cervicovaginal contents Brazil KJ651893 KJ624055
Candida albicans HC01INC Cervicovaginal contents Brazil KJ651894 KJ624056
Candida albicans HC02INC Cervicovaginal contents Brazil KJ651895 KJ624057
Candida albicans HC03INC Cervicovaginal contents Brazil KJ651896 KJ624058
Candida albicans HC04INC Cervicovaginal contents Brazil KJ651897 KJ624059
Candida albicans HC05INC Cervicovaginal contents Brazil KJ651898 KJ624060
Candida albicans HC06INC Cervicovaginal contents Brazil KJ651899 KJ624061
Candida albicans HC07INC Cervicovaginal contents Brazil KJ651900 KJ624062
Candida albicans HC08INC Cervicovaginal contents Brazil KJ651901 KJ624063
Candida albicans HC09INC Cervicovaginal contents Brazil KJ651902 KJ624064
(–) data not provided; HC: clinical hospital/UFPR; C: colonized; IC: complicated infection; INC: non-complicated infection.
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(5′-GGTCCGTGTTTCAAGACGG-3′) were used following the
same reaction conditions, as listed above.19
For ABC genotyping of C. albicans, the primers CA-int-L (5′-
ATAAGGGAAGTCGGCAAAATAGATCCGTAA-3′) and CA-int-R
(5′-CCTTGGCTGTGGTTTCGCTAGATAGTAGAT-3′) were used.20
The genotyping was based on the presence or absence of a
DNA insert, which codes for the ribosomal 26S RNA, divid-
ing C. albicans in four groups20: A (C. albicans – 450 bp), B (C.
albicans – 840 bp), C (C. stellatoidea – 840 bp) and D (C. dubliniensis
– 1080 bp).
Alignment  and  phylogenetic  construction
The obtained sequences were edited using the Staden pro-
gram version 1.6, and were compared by the BLAST program
for detection of the similarities using reference sequences
available in the data bank (NCBI, National Center for Biotech-
nology Information – http://www.ncbi.nlm.nih.gov/).21,22 The
Mafft program (http://mafft.cbrc.jp/alignment/server/) was
used for the alignment; and visual inspection was done by
MEGA 5.1 version.23 Forty sequences of Candida isolates were
submitted for phylogenetic analysis using Schizosaccharomyces
pombe strain U40085 as outgroup.20 The Maximum Likelihood
phylogenetic tree was built with 100 bootstraps, based on the
evolutionary model Tamura-3 parameters with using 5.1 ver-
sion of the MEGA software for ﬁnal editing.23
In  vitro  susceptibility  tests
The in vitro susceptibility tests were done by micro-dilution
method of broth, as per the Norm M27-A3 recommendations
provided by the Clinical and Laboratory Standards Institute.24
The antifungals used were amphotericin B (Sigma–Aldrich
110 Química, Madrid, Spain), ketoconazole (Pharma Nos-
tra, Brazil), itraconazole (Fragon), ﬂuconazole (Pﬁzer, Madrid,
Spain) and nystatin (Pharma Nostra, Brazil). The samples were
diluted in RPMI (Roswell Park Memorial Institute Medium)-
1640 medium (Sigma) and incubated at 37 ◦C for 48 h.
According to the CLSI criteria, the sensitivity proﬁle is clas-
siﬁed as sensitive, dose-dependent sensitivity and resistant.
Results
A total of 40 isolates were obtained from 133 cervicovaginal
samples, which were previously identiﬁed by CHROMagar and
API 20AUX systems. On the basis of ITS and D1/D2 sequences,
the isolates could be attributed to the genera Candida and Sac-
charomyces (Table 1). Among the isolates studied, 20 belonged
to the colonized group, 11 were from the complicated infection
group and 9 were from the uncomplicated infection group.
A tree was constructed using maximum likelihood analy-
sis and the evolutionary model Kimura 2-parameter with 100
bootstraps. A total of 1959 sites were evaluated, of which, 786
were conserved sites, 1092 were variable sites, 712 sites pro-
vided parsimonious information (pi), and 361 were unique
sites. The empirical basis frequencies were pi (A): 0.225836
pi (C): 0.283009 pi (G): 0.238533, pi (t) 0.252622. The phyloge-
netic tree was generated by using 18 strains as references,
which included various types of strains of Candida species, b i o l o g y 4 7 (2 0 1 6) 373–380
Kluyveromyces marxianus,  K. lactis, Saccharomyces cerevisiae,
Torulaspora delbrueckii,  keeping Schizosaccharomyces pombe as an
outgroup.
The evaluated VVC isolates were identiﬁed to be C. albicans,
C. dubliniensis, C. guilliermondii, C. kefyr, Saccharomyces cerevisiae
and C. glabrata and were found to be distributed into six clades
supported by bootstrap values (Fig. 1). The phylogenetic data
corroborated with the biochemical data, except for the HC03IC
isolate that was identiﬁed as C. albicans by the API 20AUX sys-
tem, but as C. dubliniensis by the phylogenetic analysis (Fig. 1).
According to the tree, most of the analyzed clinical isolates
were identiﬁed to be C. albicans, with 33 isolates clustered in
Albicans clade (bs, 100%). Analysis revealed that C. albicans iso-
lates could not be separated according to the studied groups,
i.e., colonized, complicated, and uncomplicated infection
groups. In Guilliermondii clade (bs, 99%), the clinical isolate
(HC08C) and P. guilliermondii (NRRL Y-2075) type strain were
grouped. The isolate (HC02C) from the colonized group and
Saccharomyces cerevisiae type were clustered in Saccharomyces
clade (bs, 100%). Kefyr clade consisted of Kluyveromyces marx-
ianus (NRRL Y-8281), Candida kefyr teleomorph strain CBS 712,
K. marxianus var. Kluyveromyces lactis strain NRRL Y-8279 and
HC09C isolate of C. kefyr. Three isolates were classiﬁed into
the Glabrata clade (HC01C, HC07C and HC10C), belonging to
the colonized group and C. glabrata type (5478) with 100% boot-
strap.
Based on the molecular data, amidst the 40 isolates that
were obtained from vaginal samples, the most prevalent
species was C. albicans (82.5%), followed by C. glabrata (7.5%),
C. guilliermondii (2.5%), C. kefyr (2.5%), C. dubliniensis (2.5%) and
Saccharomyces cerevisiae (2.5%). Among the colonized group
alone, a total of 20 isolates belonging to ﬁve different species
C. albicans (60%), C. glabrata (25%), C. guilliermondii (5%), C. kefyr
(5%) and Saccharomyces cerevisiae (5%) were identiﬁed. A total
of 9 isolates obtained from the uncomplicated infection group
were C. albicans (100%). In the complicated infection group, 11
isolates were from two different Candida species: C. dubliniensis
(9.1%) and C albicans (90.9%).
Regarding the ABC genotyping of C. albicans, at least two  dif-
ferent genotypes (A and B) were observed, although 25 isolates
belonged to type A and 7 isolates to type B, it was not possible
to establish a correlation amidst the genotypes identiﬁed and
the susceptibility proﬁle of the tested drugs (Fig. 2).
The susceptibility testing results of the studied isolates
from different patient groups are summarized in Table 2. In
the colonized group (I), all isolates of C. albicans (n = 14) showed
a dose-dependent sensitivity (SDD) to nystatin (8.0 g/mL)
and sensitivity (S) to itraconazole (0.0625 g/mL), ﬂuconazole
(0.125 g/mL), amphotericin B (0.03–1.0 g/mL) and ketocona-
zole (0.0625 g/mL). Three C. glabrata isolates (HC01C, HC02C
and HC07C) were resistant (R) to itraconazole (4.0 g/mL), SDD
for the ﬂuconazole (4.0–16 g/mL), nystatin (8.0 g/mL) and
sensitive to amphotericin B (0.03–1.0 g/mL) and ketocona-
zole (1.0–4.0 g/mL). The isolate of C. guilliermondii (HC16C)
showed SDD to nystatin (8.0 g/mL), resistance to ampho-
tericin B (2.0 g/mL), sensitivity to itraconazole (0.0625 g/mL),
ﬂuconazole (0.125 g/mL), and ketoconazole (0.0625 g/mL).
C. kefyr (HC09C) presented SDD to itraconazole (0.25), nys-
tatin (4.0 g/mL), and sensitivity for ﬂuconazole (0.25 g/mL),
amphotericin B (1.0 g/mL) and ketoconazole (0.0625 g/mL).
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Clade: Albicans
Clade: Dubliniensis
Clade: Guilliermondii
Clade: Saccharomyces
Clade: Kefyr
Clade: Glabrata
15C Candida albicans
14C Candida albicans
11C Candida albicans
09INC Candida albicans
12C Candida albicans
05C Candida albicans
04C Candida albicans
100 100
100
100
100
100
100
100
100
100
100
100
100100
100
100
0.05
100
100
100
99
97
98
98
96
95
94
100
96
06C Candida albicans
13C Candida albicans
17C Candida albicans
07INC Candida albicans
06IC Candida albicans
04IC Candida albicans
05IC Candida albicans
08IC Candida albicans
11IC Candida albicans
01IC Candida albicans
10IC Candida albicans
02IC Candida albicans
03C Candida albicans
9IC Candida albicans
18C Candida albicans
CBS2030 Pichia guilliermondii
CBS2285 Debaryomyces carsonii
CECT10-210 Pichia segobiensis
CBS4159 Candida haemulonii
CBS572 Candida intermedia
CBS180 Candida inconspicua
L1B Pichia fermentans
CBS1146 Torulaspora delbrueckii
CBS712 Kluyveromyces marxianus
CECT1961 Kluyveromyces lactis
U44808 AY198398 Candida glabrata
9C Candida kefyr
02C Saccharomyces cerevisiae
01C Candida glabrata
U40085  Schizosaccharomyces pombe
10C Candida glabrata
07C Candida glabrata
NRRLY12632 Saccharomyces cerevisiae
23 Pichia membranifaciens
CBS6986 Clavispora lusitaniae
08C Candida guilliermondii
07IC Candida albicans
02INC Candida albicans
08INC Candida albicans
03IC Candida dubliniensis
CBS94 Candida tropicalis
CBS7987 Candida dubliniensis
04INC Candida albicans
19C Candida albicans
20C Candida albicans
16C Candida albicans
06INC Candida albicans
03INC Candida albicans
01INC Candida albicans
05INC Candida albicans
CBS562 Candida albicans
Fig. 1 – The phylogenetic tree of maximum likelihood based on the alignment of the entire region of its1/its2 and D1/D2 was
built using 100 bootstrap, using the evolutionary model Tamura-3 parameters with program Mega version 5.1.
Schizosaccharomyces pombe was used as an outgroup. The tree showed 6 clades (Albicans; Dubliniensis; Guilliermondii,
Saccharomyces; Kefyr; Glabrata) diversiﬁed according to the isolated species. For a thorough understanding, the evaluated
groups in this study are represented by colored squares for discernment: the brown square refers to the colonized group;
one red square indicates isolates from the uncomplicated infection group; the two red squares represent the group with
complicated infection.
378  b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 (2 0 1 6) 373–380
2500
1500
500
750
1000
2000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
M MBHC
2C
HC
3C
HC
4C
HC
5C
HC
6C
HC
11
C
HC
12
C
HC
14
C
HC
15
C
HC
17
C
HC
18
C
HC
19
C
HC
20
C
HC
1IN
C
HC
2IN
C
HC
3IN
C
HC
4IN
C
HC
5IN
C
HC
6IN
C
HC
7IN
C
HC
8IN
C
HC
9IN
C
HC
1IC
HC
2IC
HC
3IC
HC
4IC
HC
5IC
HC
6IC
HC
7IC
HC
8IC
HC
9IC
HC
10
IC
Fig. 2 – Agarose electrophoresis ABC genotyping of the C. albicans from the different studied groups, genotype A (C. albicans
– 450 bp) and B (C. albicans – 840 bp). The lanes 2–14 correspond to the colonized group; 15–23 to the uncomplicated infection
group and 24–33 to the complicated infection group. Lane 34 represents a blank; the lanes 1 and 35 indicate standard 1 kb
molecular weight markers (Invitrogen, Carlsbad, Ca, USA).
Furthermore, S. cerevisiae isolate (HC02C) was SDD to nystatin
(8.0 g/mL) and sensitive to itraconazole (0.0625 g/mL), ﬂu-
conazole (0.125 g/mL), amphotericin B (0.03–1.0 g/mL) and
ketoconazole (0.0625 g/mL).
In the complicated infection group (II), one strain of
C. albicans isolate (HC01IC) was found to be SDD to
itraconazole (0.0625–0.25 g/mL); all isolates (n = 10) were
resistant to nystatin (≥64 g/mL) and sensitive to ﬂu-
conazole (0.125–2.0 g/mL), amphotericin B (1.0 g/mL) and
ketoconazole (0.0625 g/mL). C. dubliniensis isolate (HC03IC)
was resistant to nystatin (≥64 g/mL) and presented sen-
sitivity toward the itraconazole (0.0625 g/mL), ﬂuconazole
(0.125–2.0 g/mL), amphotericin B (0.5–1.0 g/mL) and keto-
conazole (0.0625 g/mL). Finally, in the uncomplicated infec-
tions group (III), all the isolates (n = 9) of C. albicans were
SDD to nystatin (8.0 g/mL) and sensitive toward itraconazole
(0.0625 g/ml), ﬂuconazole (0.125–2.0 g/mL), amphotericin B
(0.5–1.0 g/mL) and ketoconazole (0.0625 g/mL).
DiscussionIdentiﬁcation of Candida species that causes VVC is highly
desirable in microbiological practice, as it may help in clar-
ifying the prevalence and incidence of species that affects
Table 2 – Variations in the minimum inhibitory concentration (
Isolate species Total of samples Itraconazole Fluco
C. albicans (I) 14 0.0625–0.0625 0.125–0
C. albicans (II) 10 0.0625–0.25 (SDD = 1) 0.125–2
C. albicans (III) 09 0.125–0.125 0.125–0
C. glabrata (I) 03 2.0–4.0 (R = 3) 4.0–16.0
C. guillermondii (I) 01 0.0625–0.0625 0.125–8
C. Kefyr (I) 01 0.25 (SDD = 1) 0.25 
S. cerevisiae (I) 01 0.0625–0.0625 0.125–0
C. dubliniensis (II) 01 0.0625–0.0625 0.125–2
SDD: sensitivity dose dependent; R: resistant; S: sensitivity; I: colonized grthe susceptible population. Moreover, determination of sus-
ceptibility of Candida to the antifungal drugs may be crucial
in context of the recurrent clinical forms of VVC. Several
studies have demonstrated the occurrence of vulvovaginitis
due to Candida species, indicating heterogeneity among iso-
lates from different geographical regions. In the present study,
the prevalent species were3,25–27 C. albicans, followed by C.
glabrata, C. guilliermondii, C. kefyr, C. dubliniensis and Saccha-
romyces cerevisiae, thereby suggesting an increase of infection
by non-albicans Candida. An increase in infections that are
caused by non-albicans Candida has been registered, although
C. albicans is still the most isolated species in VVC clinical
cases.13,28–31 Furthermore, the cultural and ethnic differences
may also inﬂuence the isolation rate of yeast from vulvovagini-
tis samples.32,33 The lack of data on epidemiology and genetic
variability reinforces the importance of epidemiological stud-
ies by molecular methods.6,27,34–36
The colonized group investigated in the current study
presented a wide diversity of species such as C. albicans,
C. glabrata, C. guilliermondii, C. kefyr and Saccharomyces cere-
visiae. In addition, C. albicans was found to be prevalent
(n = 19) in the infection group and C. dubliniensis (n = 1) iso-
lates were observed only in the complicated infection group
(Table 2). The microbiota species found in colonized women
are the same as reported in VVC.1,4,27,30,35 Vaginitis caused by
MIC) of antifungals for the different study groups.
nazole Nystatin Amphotericin B Ketoconazole
.125 8.0–8.0 (SDD=14) 0.03–1.0 0.0625–0.0625
.0 ≥64 (R = 10) 0.5–1.0 0.0625–0.25
.125 8.0–8.0 (SDD = 9) 1.0–1.0 0.0625–0.0625
 (SDD = 1) 8.0–8.0 (SDD = 3) 0.03–1.0 1.0–4.0
.0 8.0 (SDD = 1) 0.25–2.0 (R = 1) 0.0625–2.5
4.0 (SDD = 1) 1.0 0.0625
.125 8.0–8.0 (SDD = 1) 0.03–1.0 0.0625–0.0625
.0 ≥ 64 (R = 1) 0.5–1.0 0.0625–0.25
oup; II: complicated infection group; III: uncomplicated group.
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. cerevisiae is rare and it has been isolated from an asymp-
omatic patient.37,38 This corroborates with the ﬁndings of the
resent study.
The VVC Candida albicans isolates, analyzed by us, were
lustered into a single clade, indicating a monophyletic group
Fig. 1), which is in concordance with the data already reported
y several authors.31,39 The strain, identiﬁed as C. albicans
HC03IC) by biochemical test, proved to be C. dubliniensis
ccording to the phylogenetic analysis. A lack of correlation
etween the phenotypic and molecular identiﬁcation of the
amples can be justiﬁed by the limitations of the commercial
dentiﬁcation system, which do not allow distinguishing the
east species, which have minor phenotypic differences.40,41
herefore, multilocus analyses are needed in order to identify
andida species.31 In the ABC genotyping, two different geno-
ypes among C. albicans isolates were detected. The genotype
 was observed in 75.7% of the isolates, and the isolates of
enotype B were present in all the analyzed groups. However, it
ad a higher occurrence in the uncomplicated infected group
Fig. 2). It has been reported that the candidiasis that is caused
y C. albicans of genotype B has a higher tendency for persis-
ent infections, though further studies with larger populations
or a better assessment are required.36
In the current analysis, all the C. albicans isolates from the
omplicated group, regardless of genotype, were resistant to
ystatin and susceptible to other tested antifungals, except
or the isolate HC04IC that showed SDD to ﬂuconazole. In the
ncomplicated infections group, the isolates of C. albicans were
DD to nystatin and susceptible to other tested antifungals.
he same was observed in the isolates from the group of colo-
ized patients. Concerning the non-albicans Candida species,
he isolate of C. dubliniensis was resistant only to nystatin, the
. glabrata isolates were resistant to itraconazole and SDD to
uconazole and nystatin. These results contrast from the pre-
ious reports that regarded C. glabrata isolates as resistant and
DD to ﬂuconazole.42 Besides, C. kefyr strain presented SDD
o itraconazole and nystatin, and a similar susceptibility pro-
le was previously reported.10 In other studies, similar results
ere obtained, reporting that VVC species strains of genus
andida presented resistance and also a high frequency of SDD
or nystatin and sensitivity to others tested drugs.26,35,43
The isolate of C. guilliermondii showed SDD to nystatin
nd resistance to amphotericin B. According to the literature,
he treatment is problematical due to a low sensitivity for
ome antifungal classes, especially for ﬂuconazole, itracona-
ole and amphotericin B; and VVC infections caused by C.
uilliermondii are rare.2 Furthermore, we obtained an isolate of
. cerevisiae SDD to nystatin, which differed from the data pre-
iously reported for this species, which demonstrated that S.
erevisiae isolates were resistant to ﬂuconazole, posaconazole,
nd itraconazole.44
There are several factors that can inﬂuence the clini-
al response to treatment of VVC, as evident from different
eports showing variation in the in vitro susceptibility and
n vivo response to the drug.39,45 Through in vitro susceptibility
esting, it was observed that all the isolates were sensitive to
etoconazole, although ﬂuconazole remains the drug of choice
or VVC treatment. Such results indicate that the susceptibility
roﬁle for the isolates may not be a factor related to the recur-
ence of the disease. Therefore, it may be concluded that theo l o g y 4 7 (2 0 1 6) 373–380 379
molecular analysis provides accurate identiﬁcation of Candida
species isolated from patients with VVC. Hence, our ﬁndings
demonstrated the importance of molecular tools for identiﬁ-
cation of the isolates and also to elucidate the epidemiology
of VVC.
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